RGnomics: "Joint Research on RNA Editing Therapy with Lilly Progressing Smoothly"

"Joint Research on Genetic Hearing Loss Treatment Progressing Smoothly"

"Collaboration with Lilly Advancing as Planned"

"Validation of RNA Editing Technology and Expanded Global Partnerships"

RGnomics announced on August 21 that its joint research with global pharmaceutical company Eli Lilly on a treatment for genetic hearing loss is proceeding smoothly according to the research plan agreed upon by both companies.

Last year, RGnomics and Lilly signed a global license and joint research agreement to develop a treatment for hereditary sensorineural hearing loss using RGnomics' RNA editing technology platform, "trans-splicing ribozyme."

According to the agreement, RGnomics is conducting early-stage research based on the research and development plan agreed upon by both companies. In subsequent development stages, Lilly will be responsible for follow-up development and commercialization.

The two companies regularly hold a Joint Research Committee (JRC) to share the progress and main outcomes of the research. They are also discussing future research and development plans.

A representative from RGnomics stated, "The joint research with Lilly is progressing smoothly in accordance with the research plan agreed upon by both parties. Not only are we successfully accomplishing the first collaborative project, but we also expect that, based on the accumulated research achievements and mutual trust, our partnership with Lilly will expand to cover additional projects and new areas."

The representative added, "Through joint research with a global pharmaceutical firm, we are continuously building experience and data in applying our RNA editing platform to real-world drug development. Based on this, we plan to expand global partnerships across a variety of genetic disease areas."

This content was produced with the assistance of AI translation services.